A previous drug screen conducted in our laboratory identified the ATP-competitive AKT inhibitor AZD5363 as a drug which could preferentially slow the growth of MCF10A (non-malignant breast) and NCI-N87 (gastric cancer) cells that are deficient in E-cadherin [9]. Here, AKT1 is linked to gastric cancer.